Australia to begin human trials for COVID-19 vaccine made by China
Category: #headlines  By Anchal Solanki  Date: 2020-04-29
  • share
  • Twitter
  • Facebook
  • LinkedIn
Australia to begin human trials for COVID-19 vaccine made by China

Linear Clinical Research, a research and clinical facility in Perth, Australia, has confirmed a human trial of a coronavirus vaccine that has been developed by China. Sources familiar with the matter said that research and clinical facility has already initiated the recruitment of healthy adults to participate in the trial within the coming two months.

S-Trimer vaccine, which is primarily developed by a biotechnology company called Clover Biopharmaceuticals, located in China, is believed to be one of the first COVID-19 vaccines to be under development. Linear had also made an announcement regarding the vaccine trial on the website and also called on the people who are interested in being registered with the company.

The company issued the statement that if people were feeling unhealthy and were located in Perth, WA, they could register their interest to be able to participate in the forthcoming COVID-19 vaccine study of the company.

According to a reliable source, the protein-based vaccine S-Trimer, is aimed at helping the body in producing anti-bodies to fight the virus.

Jayden Rogers, Linear’s chief executive commented that the trial was among the most vital trials across the globe and involves some extremely renowned vaccine firms. The S-Trimer vaccine had shown promising potential on the trial and has been placed at the forefront of the world’s battle with coronavirus pandemic.

The Chinese authorities had approved the human testing for two other COVID-19 vaccines recently in the month of April that were developed by the Wuhan Institute of Biological Products. This was done under the Sinovac Research and Development Co and China National Pharmaceutical Group (Sinopharm).

Apparently, Sinopharm has been able to produce more than 50,000 doses for the clinical trials. Once the production gets normalized, the output is capable of reaching about 3 million doses per batch and an annual output would be at 100 million doses.

 

Source Credit- https://www.aa.com.tr/en/asia-pacific/australia-set-for-chinese-covid-19-vaccine-human-trial-/1821328

 

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Anchal Solanki

Anchal Solanki    

A civil engineer by qualification, Anchal Solanki forayed into the domain of content writing in the midst of her graduation, embarking on the career path of a successful freelancer. Equipped with a short-term experience in market research, Anchal currently writes news...

Read More >>

More News By Anchal Solanki

Open Systems inks an acquisition deal with Born in the Cloud
Open Systems inks an acquisition deal with Born in the Cloud
By Anchal Solanki

Open Systems, a secure access service edge (SASE) solution company based out in Switzerland, has recently announced that it has purchased Born in the Cloud, a Microsoft Gold-Certified partner company that provides threat prevention, detection, and re...

PG&E announces plans to expand battery energy storage capacity
PG&E announces plans to expand battery energy storage capacity
By Anchal Solanki

Pacific Gas and Electric Company, the American combined natural gas and electric service company, has reportedly filed an application to CPUC (California Public Utilities Commission) for getting approval on five energy storage projects. Sources cite...

Siemens Gamesa introduces 14 MW offshore wind turbine with 222m rotor
Siemens Gamesa introduces 14 MW offshore wind turbine with 222m rotor
By Anchal Solanki

Non-exhaustible energy sources have evolved as one of the best alternative energy sources and have gained recognition and importance on a global scale. Having understood their exceptional advantages over traditional power sources, companies worldwide...